Mazdutide vs Retatrutide: Two Glucagon-Pathway Drugs
Mazdutide vs retatrutide: GLP-1/glucagon dual agonist vs GIP/GLP-1/glucagon triple agonist, regulatory status and report links. Not medical advice.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
Mazdutide (developed by Innovent with Lilly) is a GLP-1/glucagon dual agonist that has received approval in China for weight management; it is not FDA-approved. Retatrutide is Lilly's investigational triple agonist (GIP/GLP-1/glucagon). Different molecules, regions and evidence stages. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
What users report here
Anonymous accounts are collected on the Retatrutide reports. They are personal stories, often with other compounds in the mix, not evidence of effect.
related peptides:
community guides:
More confessions from the archive
Community Q&A
- Is mazdutide approved in the US?
- No. Its first approvals were in China.
- Is mazdutide a triple agonist?
- No — GLP-1 and glucagon. Retatrutide is the triple agonist.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.